EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak und 2 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06025-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Heidi Mocikova und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fakultni nemocnice Kralovske Vinohrady, Department of Haematology and Third Faculty of Medicine, Charles University, Prague, Czech Republic. heidi.mo…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Testicular Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charles University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with testicular lymphoma are at an increased risk of central nervous system (CNS) disease. Optimal strategy for CNS relapse prevention is unknown. We analyzed treatment strategies, cumulative incidence of CNS relapse and prognosis in 229 patients with diffuse large B-cell lymphoma (DLBCL) and testicular involvement: 157 primary testicular lymphomas (PTL) in clinical stages IE/IIE and 72 patients in advanced stages (T-DLBCL) IIIE/IV. Treatments for PTL vs. T-DLBCL included: rituximab-based chemotherapy (80.9% vs. 90.3%), orchiectomy (94.3% vs. 65.3%) and contralateral testicular irradiation (59.8% vs. 44.4%). Majority (84.3%) received CNS prophylaxis with similar rates of prophylactic methotrexate (intravenous 19.1% vs. 16.6%, intrathecal 40.8% vs. 40.4%, or both 24.2% vs. 27.8%) between PTL and T-DLBCL ( p = 0.89). Median follow-up was 51.8 months. CNS relapses occurred in 14 (6.1%) of 63 relapsing patients. The 5-year cumulative incidence of CNS relapse in PTL was 4.5% and in T-DLBCL 12.1%. Median time to CNS relapse was 21.9 months. In univariate analyses, orchiectomy was the single significant factor associated with lower risk of CNS relapse in PTL (HR = 0.11 [95% CI, 0-0.124], p = 0.001). Rituximab significantly reduced CNS relapse risk in T-DLBCL (HR = 0.1002, p = 0.0005). Median progression-free survival (PFS) and overall survival (OS) following CNS relapse was dismal in T-DLBCL compared to PTL (PFS 1.6 vs. 37.8 months, p = 0.04 and OS 2.3 vs. 37.8 months, p = 0.05). This study confirmed a favorable impact of rituximab in prevention of CNS relapse in T-DLBCL. Methotrexate prophylaxis did not alter CNS relapse risk. Prognosis of CNS relapse is particularly poor in T-DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseTesticular NeoplasmsHumansMaleMiddle AgedAgedAdultRituximabCentral Nervous System NeoplasmsAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsMethotrexateRetrospective StudiesOrchiectomyTreatment OutcomeFollow-Up StudiesYoung AdultPrognosis

Stichwörter der Autor:innen

CNS relapseDiffuse large B-cell lymphomaOrchiectomyRituximabTesticular involvement

Substanzen

RituximabMethotrexate

Autor:innen und Institutionen

  • Fakultni nemocnice Kralovske Vinohrady, Department of Haematology and Third Faculty of Medicine, Charles University, Prague, Czech Republic. heidi.mocikova@seznam.cz.
  • Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University Brno, Brno, Czech Republic.
  • University Hospital and Faculty of Medicine, 4th Department of Internal Medicine- Hematology, Hradec Kralove, Czech Republic.
  • Faculty of Medicine and Dentistry, Department of Haemato-Oncology, Palacky University, Olomouc, Czech Republic.
  • Ceske Budejovice Hospital, Ceske Budejovice, Czech Republic.
  • University Hospital and Faculty of Medicine, Department of Hemato-Oncology, Ostrava, Czech Republic.

Förderung

  • Charles University

Zitieren

APA

Mocikova, H., Janikova, A., Sykorova, A., Prochazka, V., Pirnos, J., Duras, J., Kopeckova, K., Steinerova, K., Pytlik, R., Blahovcova, P., Salek, D., Kozak, T., Bachanova, V., & Belada, D. (2024). Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data. Annals of Hematology. https://doi.org/10.1007/s00277-024-06025-y

Vancouver

Mocikova H, Janikova A, Sykorova A, Prochazka V, Pirnos J, Duras J, et al. Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data. Annals of Hematology. 2024. doi:10.1007/s00277-024-06025-y

BibTeX
@article{Mocikova2024,
  author = {Mocikova, Heidi and Janikova, Andrea and Sykorova, Alice and Prochazka, Vit and Pirnos, Jan and Duras, Juraj and Kopeckova, Katerina and Steinerova, Katerina and Pytlik, Robert and Blahovcova, Petra and Salek, David and Kozak, Tomas and Bachanova, Veronika and Belada, David},
  title = {Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06025-y}
}
Kostenlos starten →